In chronic myelogenous leukemia, a tyrosine kinase inhibitor (imatinib) activated FOXO1 and FOXO3 by blocking the PI3K-AKT pathway, and in turn induced cell-cycle arrest and apoptosis [21]. Here, AKT1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.